KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to -$90.9 million.

  • Xenon Pharmaceuticals' Income towards Parent Company fell 4476.19% to -$90.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$320.2 million, marking a year-over-year decrease of 5005.01%. This contributed to the annual value of -$248.2 million for FY2024, which is 3607.16% down from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Income towards Parent Company stood at -$90.9 million for Q3 2025, which was down 4476.19% from -$84.7 million recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Income towards Parent Company ranged from a high of -$15.4 million in Q3 2021 and a low of -$90.9 million during Q3 2025
  • Over the past 5 years, Xenon Pharmaceuticals' median Income towards Parent Company value was -$44.7 million (recorded in 2023), while the average stood at -$46.1 million.
  • Per our database at Business Quant, Xenon Pharmaceuticals' Income towards Parent Company crashed by 1253371.43% in 2021 and then plummeted by 1486.81% in 2024.
  • Xenon Pharmaceuticals' Income towards Parent Company (Quarter) stood at -$25.6 million in 2021, then plummeted by 46.45% to -$37.4 million in 2022, then decreased by 19.51% to -$44.7 million in 2023, then tumbled by 77.77% to -$79.5 million in 2024, then decreased by 14.28% to -$90.9 million in 2025.
  • Its last three reported values are -$90.9 million in Q3 2025, -$84.7 million for Q2 2025, and -$65.0 million during Q1 2025.